FDA Says Glaxo Failed to Report Avandia Data
WASHINGTON (Reuters) - GlaxoSmithKline Plc <GSK.L> <GSK.N>
failed to report all of the required post-approval data on its
diabetes drug Avandia to U.S. regulators, the Food and Drug
Administration said in a warning to the company released on
Tuesday.